Advertisement
Screener

EDESA BIOTECH, INC. (EDSA) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

EDESA BIOTECH, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

EDESA BIOTECH, INC. (EDSA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 97.26% for the 12-month period ending 2024-09-30, per its 10-K filed 2025-12-12.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2025-12-12

  • EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-12-31 was 97.26%, a 2.06% increase year-over-year.
  • EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-12-31 was 95.30%, a 2.04% decline year-over-year.
  • EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2021-12-31 was 97.28%, a 0.00% change year-over-year.
  • EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2020-12-31 was 97.28%.
  • EDESA BIOTECH, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 97.26%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2024-09-3097.26%
10-K · filed 2025-12-12
2024-06-3097.26%
10-Q · filed 2025-08-08
2024-03-3197.26%
10-Q · filed 2025-05-14
2023-12-3197.26%
10-Q · filed 2025-02-14
2022-12-3195.30%
10-Q · filed 2024-02-09
2021-12-3197.28%
10-Q · filed 2022-02-14
2020-12-3197.28%
10-Q · filed 2021-02-16
2020-06-30104.14%
10-Q · filed 2021-08-13
2020-03-31104.14%
10-Q · filed 2021-05-14
2019-09-3079.46%
10-K · filed 2020-12-07
2019-06-3079.46%
10-Q · filed 2020-08-12
2019-03-3179.46%
10-Q · filed 2020-05-15
2018-12-3179.46%
10-Q · filed 2020-02-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
CervoMed Inc. (CRVO)United States$0.038B-1.39
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
Celularity Inc (CELU)United States$0.038B-0.34
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
PMGC Holdings Inc. (ELAB)United States$0.037B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
BriaCell Therapeutics Corp. (BCTX)$0.037B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
Kairos Pharma, LTD. (KAPA)United States$0.041B